论文部分内容阅读
[目的]评价PTEN表达水平与转移性结直肠癌(mCRC)患者西妥昔单抗临床获益之间的关系,为临床用药和个性化治疗提供参考。[方法]计算机检索PubMed、CNKI、CBM和万方中文数据库,采用Meta分析的方法,评价PETN表达与mCRC患者西妥昔单抗疗效的关系。[结果]共纳入文献14篇,病人总人数1 227人。未经K-ras基因筛选mCRC患者PTEN表达阳性与西妥昔单抗治疗敏感性及无进展生存(PFS)均相关。K-ras野生型mCRC患者PTEN表达阳性与西妥昔单抗治疗PFS、总生存(OS)获益有关。[结论]PTEN表达水平可以作为mCRC患者西妥昔单抗临床获益的预测因素。
[Objective] To evaluate the relationship between the expression of PTEN and clinical benefit of cetuximab in patients with metastatic colorectal cancer (mCRC), and to provide reference for clinical medication and personalized treatment. [Methods] The PubMed, CNKI, CBM and Wanfang Chinese databases were searched by computer. Meta analysis was used to evaluate the relationship between PETN expression and the efficacy of cetuximab in mCRC patients. [Results] A total of 14 articles were included, and the total number of patients was 1 227. The positive expression of PTEN in patients with mCRC without K-ras gene screening was correlated with the sensitivity and progression-free survival (PFS) of cetuximab. The positive expression of PTEN in K-ras wild-type mCRC patients is associated with the benefit of cetuximab in treatment of PFS and overall survival (OS). [Conclusion] The expression level of PTEN can be used as a predictor of the clinical benefit of mCRC in patients with cCR.